NCCN task force report: Update on the management of patients with gastrointestinal stromal tumors

George D. Demetri, Margaret Von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W T Pisters, Chandrajit P. Raut, Richard F. Riedel, Scott Schuetze, Hema M. Sundar, Jonathan C. Trent, Jeffrey D. Wayne

Research output: Contribution to journalReview article

582 Citations (Scopus)

Abstract

The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate. A better understanding of the molecular characteristics of GISTs have improved the diagnostic accuracy and led to the discovery of novel immunomarkers and new mechanisms of resistance to TKI therapy, which in turn have resulted in the development of novel treatment strategies. To address these issues, the NCCN organized a task force consisting of a multidisciplinary panel of experts in the fields of medical oncology, surgical oncology, molecular diagnostics, and pathology to discuss the recent advances, identify areas of future research, and recommend an optimal approach to care for patients with GIST at all stages of disease. The task force met for the first time in October 2003 and again in December 2006 and October 2009. This supplement describes the recent developments in the field of GIST as discussed at the October 2009 meeting.

Original languageEnglish (US)
Pages (from-to)S1-S40
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume8
Issue numberSUPPL. 2
StatePublished - Apr 1 2010

Fingerprint

Gastrointestinal Stromal Tumors
Advisory Committees
Protein-Tyrosine Kinases
Medical Oncology
Molecular Pathology
Standard of Care
Patient Care
Therapeutics

Keywords

  • Abdominal tumor
  • CD117
  • GEP
  • GIST
  • Gastric mass
  • Gastrointestinal stromal tumor
  • Gastrointestinal tract
  • Gene expression profiling
  • Imatinib
  • KIT
  • Liver metastasis
  • NCCN
  • PDGFRA
  • Small bowel tumor
  • Stomach cancer
  • Sunitinib
  • TKIs
  • Tyrosine kinase inhibitors
  • Wild-type GISTs

ASJC Scopus subject areas

  • Oncology

Cite this

Demetri, G. D., Von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., Maki, R. G., ... Wayne, J. D. (2010). NCCN task force report: Update on the management of patients with gastrointestinal stromal tumors. JNCCN Journal of the National Comprehensive Cancer Network, 8(SUPPL. 2), S1-S40.
Demetri, George D. ; Von Mehren, Margaret ; Antonescu, Cristina R. ; DeMatteo, Ronald P. ; Ganjoo, Kristen N. ; Maki, Robert G. ; Pisters, Peter W T ; Raut, Chandrajit P. ; Riedel, Richard F. ; Schuetze, Scott ; Sundar, Hema M. ; Trent, Jonathan C. ; Wayne, Jeffrey D. / NCCN task force report : Update on the management of patients with gastrointestinal stromal tumors. In: JNCCN Journal of the National Comprehensive Cancer Network. 2010 ; Vol. 8, No. SUPPL. 2. pp. S1-S40.
@article{0bbe58d0a7c74c59bebb4f9a2fb11f52,
title = "NCCN task force report: Update on the management of patients with gastrointestinal stromal tumors",
abstract = "The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate. A better understanding of the molecular characteristics of GISTs have improved the diagnostic accuracy and led to the discovery of novel immunomarkers and new mechanisms of resistance to TKI therapy, which in turn have resulted in the development of novel treatment strategies. To address these issues, the NCCN organized a task force consisting of a multidisciplinary panel of experts in the fields of medical oncology, surgical oncology, molecular diagnostics, and pathology to discuss the recent advances, identify areas of future research, and recommend an optimal approach to care for patients with GIST at all stages of disease. The task force met for the first time in October 2003 and again in December 2006 and October 2009. This supplement describes the recent developments in the field of GIST as discussed at the October 2009 meeting.",
keywords = "Abdominal tumor, CD117, GEP, GIST, Gastric mass, Gastrointestinal stromal tumor, Gastrointestinal tract, Gene expression profiling, Imatinib, KIT, Liver metastasis, NCCN, PDGFRA, Small bowel tumor, Stomach cancer, Sunitinib, TKIs, Tyrosine kinase inhibitors, Wild-type GISTs",
author = "Demetri, {George D.} and {Von Mehren}, Margaret and Antonescu, {Cristina R.} and DeMatteo, {Ronald P.} and Ganjoo, {Kristen N.} and Maki, {Robert G.} and Pisters, {Peter W T} and Raut, {Chandrajit P.} and Riedel, {Richard F.} and Scott Schuetze and Sundar, {Hema M.} and Trent, {Jonathan C.} and Wayne, {Jeffrey D.}",
year = "2010",
month = "4",
day = "1",
language = "English (US)",
volume = "8",
pages = "S1--S40",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "SUPPL. 2",

}

Demetri, GD, Von Mehren, M, Antonescu, CR, DeMatteo, RP, Ganjoo, KN, Maki, RG, Pisters, PWT, Raut, CP, Riedel, RF, Schuetze, S, Sundar, HM, Trent, JC & Wayne, JD 2010, 'NCCN task force report: Update on the management of patients with gastrointestinal stromal tumors', JNCCN Journal of the National Comprehensive Cancer Network, vol. 8, no. SUPPL. 2, pp. S1-S40.

NCCN task force report : Update on the management of patients with gastrointestinal stromal tumors. / Demetri, George D.; Von Mehren, Margaret; Antonescu, Cristina R.; DeMatteo, Ronald P.; Ganjoo, Kristen N.; Maki, Robert G.; Pisters, Peter W T; Raut, Chandrajit P.; Riedel, Richard F.; Schuetze, Scott; Sundar, Hema M.; Trent, Jonathan C.; Wayne, Jeffrey D.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 8, No. SUPPL. 2, 01.04.2010, p. S1-S40.

Research output: Contribution to journalReview article

TY - JOUR

T1 - NCCN task force report

T2 - Update on the management of patients with gastrointestinal stromal tumors

AU - Demetri, George D.

AU - Von Mehren, Margaret

AU - Antonescu, Cristina R.

AU - DeMatteo, Ronald P.

AU - Ganjoo, Kristen N.

AU - Maki, Robert G.

AU - Pisters, Peter W T

AU - Raut, Chandrajit P.

AU - Riedel, Richard F.

AU - Schuetze, Scott

AU - Sundar, Hema M.

AU - Trent, Jonathan C.

AU - Wayne, Jeffrey D.

PY - 2010/4/1

Y1 - 2010/4/1

N2 - The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate. A better understanding of the molecular characteristics of GISTs have improved the diagnostic accuracy and led to the discovery of novel immunomarkers and new mechanisms of resistance to TKI therapy, which in turn have resulted in the development of novel treatment strategies. To address these issues, the NCCN organized a task force consisting of a multidisciplinary panel of experts in the fields of medical oncology, surgical oncology, molecular diagnostics, and pathology to discuss the recent advances, identify areas of future research, and recommend an optimal approach to care for patients with GIST at all stages of disease. The task force met for the first time in October 2003 and again in December 2006 and October 2009. This supplement describes the recent developments in the field of GIST as discussed at the October 2009 meeting.

AB - The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate. A better understanding of the molecular characteristics of GISTs have improved the diagnostic accuracy and led to the discovery of novel immunomarkers and new mechanisms of resistance to TKI therapy, which in turn have resulted in the development of novel treatment strategies. To address these issues, the NCCN organized a task force consisting of a multidisciplinary panel of experts in the fields of medical oncology, surgical oncology, molecular diagnostics, and pathology to discuss the recent advances, identify areas of future research, and recommend an optimal approach to care for patients with GIST at all stages of disease. The task force met for the first time in October 2003 and again in December 2006 and October 2009. This supplement describes the recent developments in the field of GIST as discussed at the October 2009 meeting.

KW - Abdominal tumor

KW - CD117

KW - GEP

KW - GIST

KW - Gastric mass

KW - Gastrointestinal stromal tumor

KW - Gastrointestinal tract

KW - Gene expression profiling

KW - Imatinib

KW - KIT

KW - Liver metastasis

KW - NCCN

KW - PDGFRA

KW - Small bowel tumor

KW - Stomach cancer

KW - Sunitinib

KW - TKIs

KW - Tyrosine kinase inhibitors

KW - Wild-type GISTs

UR - http://www.scopus.com/inward/record.url?scp=77951875556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951875556&partnerID=8YFLogxK

M3 - Review article

C2 - 20457867

AN - SCOPUS:77951875556

VL - 8

SP - S1-S40

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - SUPPL. 2

ER -

Demetri GD, Von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG et al. NCCN task force report: Update on the management of patients with gastrointestinal stromal tumors. JNCCN Journal of the National Comprehensive Cancer Network. 2010 Apr 1;8(SUPPL. 2):S1-S40.